Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection

The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB.1 Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea...

Full description

Saved in:
Bibliographic Details
Published inClinical gastroenterology and hepatology Vol. 18; no. 13; pp. 3043 - 3045.e1
Main Authors Lee, Hye Won, Park, Jun Yong, Hong, Taegon, Park, Min Soo, Ahn, Sang Hoon
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.12.2020
Subjects
HBIG
HBsAg
CHB
HBV
Online AccessGet full text

Cover

More Information
Summary:The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB.1 Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea), has been screened from an anti–HBs-enriched phage-display library cloned from hepatitis B vaccine-boosted human blood cells and was produced in Chinese hamster ovary cells.2–4
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1542-3565
1542-7714
DOI:10.1016/j.cgh.2019.09.038